Semantic Coherence: Merus – Signal Evidence & AI Readability

[H1] Closing in on Cancer
[H2] Every Day.
At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and developing new treatments for cancer.

Multiclonics® Platform

Clinical Trials

Our Pipeline

[H1] Closing in on Cancer
[H2] Every Day.
Cancer is a devastating disease, but we’re up to the challenge and unwavering in our determination. Every day, we’re moving ahead in our mission to close in on cancer, by discovering and developing new medicines for patients.
Our innovative multispecific Multiclonic® antibody therapeutics are engineered with compelling target combinations to work against the complex mechanisms that drive cancer. At the forefront of our pipeline is petosemtamab, a novel bispecific antibody being evaluated in two phase three registrational trials for head and neck cancer.

[H2] Multispecific
antibody
platform

Our Multiclonics® therapeutics are full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that bind to multiple targets, and are manufactured with advantageous features for anti-cancer effects against the complex mechanisms that drive cancer. Multiclonics® are capable of being developed with industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity.

[H2] Established
clinical
pipeline

Our therapeutic candidates engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways by utilizing our proprietary technology platform and deep expertise in oncology. We are currently developing a broad pipeline of wholly owned and licensed Biclonics® drug candidates in the clinic with compelling target combinations and unique mechanisms of action.

[H2] Lead
asset
petosemtamab

Our lead cancer drug candidate is petosemtamab, a Biclonics® antibody targeting EGFR and LGR5. Petosemtamab has shown encouraging single agent clinical activity in previously treated, 2L+ recurrent or metastatic (r/m) head and neck cancer, and in combination with pembrolizumab in first line (1L) PD-L1+ r/m head and neck cancer, with phase three trials enrolling in both indications. An evaluation of petosemtamab monotherapy in 3L+ metastatic colorectal cancer (mCRC) and in combination with standard chemotherapy in 1L and 2L mCRC is ongoing.

[H1] Merus Multiclonics®
Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains against virtually any target. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies, using our Biclonics® and Triclonics® platforms.
These platforms allow us to functionally evaluate our antibodies by generating large numbers of diverse panels of antibodies and to functionally screen them at high throughput to lead to the discovery of therapeutic candidates with unique and innovative properties. Further, by creating antibodies that bind to multiple targets, Biclonics® and Triclonics® may be designed to have a variety of mechanisms of action against cancer, including blocking tumor cell growth and survival and mobilizing a patient’s immune response to fight cancer. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity.
[H2] Distinctive Characteristics of Multiclonics® Deliver Unique Functionality

[H2] Unique Functionality
Our Multiclonics® have been shown to retain the qualities of natural human, full-length immunoglobulin G (IgG) antibodies, including stability, long half-life and low immunogenicity.
Biclonics® are differentiated from many other bispecific antibody formats because they do not require linkers or modifications to force correct pairing of heavy and light chains nor do they require fusion proteins to add functionality. With the IgG format of natural antibodies, Biclonics® can be reliably manufactured with high yields.
Triclonics® have a unique antibody design capable of simultaneously binding three targets at once. Triclonics® have the potential to enable tumor cell-killing activity and/or to modulate the immune system to promote more robust and specific anti-tumor immune responses.

[H2] Multiclonics®
Our Multiclonics® platforms provide patented means for efficient discovery, screening and identification of multispecific antibodies capable of differentiated biology having novel target combinations and activity.

[H3] Biclonics®
Biclonics® bispecific antibodies are capable of binding two different targets in cis for dual cancer cell targeting or trans for bridging the cancer cell to an immune effector cell.

[H3] Triclonics®
Triclonics® trispecific antibodies are capable of binding three different targets.

[H3] ADClonics®
The Biclonics® format and platform is compatible with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets for improved selectivity and potency.

[H2] Multiclonics® Platforms
Our platforms use unbiased high throughput functional screening in molecular and cell-based assays to identify novel, innovative Biclonics® and Triclonics® antibodies. Our lead molecules are selected from up to thousands of candidates generated from these platforms, identifying those molecules that possess unique biology and specific characteristics for therapeutic application.

[H2] Scientific Publications
To read more about Merus platform and its leading Biclonics® technology, please follow the link below for access to scientific publications.
View Publications

[H2] Merus is now part of Genmab.
You can find the latest information on our pipeline on the Genmab Pipeline page https://www.genmab.com/antibody-science/pipeline